KDR and neoplasm: In line with our finding in PTCs, inhibition of VEGFR is known to remodel the tumor immune microenvironment59, constituting the theoretical basis of combined anti-VEGFR therapy and ICB in the treatment of advanced thyroid cancers60,61.